Loxo Oncology (NASDAQ: LOXO)was already an investors' darling thanks to impressive efficacyfor larotrectinib in a range of cancers, and after yesterday's release of an abstractto be presented at the influential American Society of Clinical Oncology (ASCO), investors are even more optimistic about the company's future.
Will this company become the next big cancer-drug maker?This Tiny Cancer Drug Upstart Just Got Even More Interesting
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться